PMID- 26330880
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150902
LR  - 20201001
IS  - 1735-0328 (Print)
IS  - 1726-6890 (Electronic)
IS  - 1726-6882 (Linking)
VI  - 14
IP  - 3
DP  - 2015 Summer
TI  - Enhanced Production of Insulin-like Growth Factor I Protein in Escherichia coli 
      by Optimization of Five Key Factors.
PG  - 907-17
AB  - Human insulin-like growth factor I (hIGF-I) is a kind of growth factor with 
      clinical signi fi cance in medicine. Up to now, E. coli expression system has been 
      widely used as a host to produce rhIGF-1 with high yields. Batch cultures as 
      non-continuous fermentations were carried out to overproduce rhIGF-I in E. coli. 
      The major objective of this study is over- production of recombinant human 
      insulin-like growth factor I (rhIGF-I) through a developed process by recruiting 
      effective factors in order to achieve the most recombinant protein. In this study 
      we investigated the effect of culture medium, induction temperature and amount of 
      inducer on cell growth and IGF-1 production. Taguchi design of experiments (DOE) 
      method was used as the statistical method. Analysis of experimental data showed 
      that maximum production of rhIGF-I was occurred in 32y culture medium at 32  degrees C 
      and 0.05 Mm IPTG. Under this condition, 0.694 g/L of rhIGF-I was produced as the 
      inclusion bodies. Following optimization of these three factors, we have also 
      optimized the amount of glucose and induction time in 5 liter top bench 
      bioreactor. Full factorial design of experiment method was used for these two 
      factors as the statistical method. 10 g/L and OD600=5 were selected as the 
      optimum point of Glucose amount and induction time, respectively. Finally, we 
      reached to a concentration of 1.26 g/L rhIGF-1 at optimum condition.
FAU - Ranjbari, Javad
AU  - Ranjbari J
AD  - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Babaeipour, Valiollah
AU  - Babaeipour V
AD  - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran. ; Department of Life Science 
      Engineering, School of New Science and Technologies, University of Tehran, Iran.
FAU - Vahidi, Hossein
AU  - Vahidi H
AD  - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Moghimi, Hamidreza
AU  - Moghimi H
AD  - Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Mofid, Mohammad Reza
AU  - Mofid MR
AD  - Department of Biochemistry, School of Pharmacy, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Namvaran, Mohammad Mehdi
AU  - Namvaran MM
AD  - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Jafari, Sevda
AU  - Jafari S
AD  - Department of Life Science Engineering, School of New Science and Technologies, 
      University of Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Iran J Pharm Res
JT  - Iranian journal of pharmaceutical research : IJPR
JID - 101208407
PMC - PMC4518120
OTO - NOTNLM
OT  - E. coli
OT  - Non- continuous fermentation
OT  - Optimization
OT  - Taguchi design of experiments
OT  - rhIGF-I
EDAT- 2015/09/04 06:00
MHDA- 2015/09/04 06:01
PMCR- 2015/06/01
CRDT- 2015/09/03 06:00
PHST- 2015/09/03 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2015/09/04 06:01 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - ijpr-14-907 [pii]
PST - ppublish
SO  - Iran J Pharm Res. 2015 Summer;14(3):907-17.